Previous 10 | Next 10 |
Second-Quarter 2021 Results and Highlights: Consolidated revenue increased 40% to $122 million Clinical Services revenue increased 37% to $101 million Pharma Services revenue increased 55% to $20 million Completed the acquisitions of Trapelo Health in April and Inivata Limited ...
AMCX, CGC, CNK, CRON, D, DKNG, ESNT, FLR, GT, IEP, LEA, MD, MGA, MGP, MMI, MODV, NCLH, NEO, NUAN, QRTEA, ROAD, SPB, SRCL, SSP, TWST, VNT, VTR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Friday's open
Neo NEO/USD is the native cryptocurrency token that powers the Neo blockchain and can be used for sending, spending, staking, and holding. The N3 mainnet launch as a catalyst for growth On August 2, Neo launched the Neo N3 mainnet which marked a huge milestone for Neo as...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips On July 14, I wrote a seven-stock gallery piece about companies I thought would do well in the second half of 2021. Included on my list was The Trade Desk (NASDAQ: TTD ) and TTD stock. Source: Tada Images...
FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its second quarter 2021, financial results on Friday, August 6, 2021. The Compa...
NEO operates a broad network of cancer-focused testing centers in the U.S., Europe, and Asia, and is actively seeking new markets to enter. Although the COVID pandemic had an adverse effect on the company’s financials, all of the laboratories and testing services remained opene...
Boarding1Now/iStock via Getty Images NeoGenomics Inc. (NEO) is a new best idea long from Hedgeye analyst Tom Tobin with potential upside to $80/share. NeoGenomics gained 1.7% . NEO's focus on community oncology testing makes the company a likely beneficiary of the post COVID return ...
NeoGenomics (NEO) has completed the previously announced acquisition of commercial stage liquid biopsy platform company Inivata.Inivata will become a liquid biopsy focused division alongside NeoGenomics' growing clinical, pharma and informatics divisions, the company said.The acquis...
Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) , a leading provider of cancer-focused genetic testing services and global oncology contract resea...
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating virtually in multiple upcoming institutional i...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...